J&J’s drug gained approved in this indication after the trial met its primary endpoint of PFS.

The epidermal growth factor receptor (EGFR) is a membrane-bound tyrosine kinase that integrates signals from multiple ligands to regulate vascular cell behaviour. Upon ligand engagement, EGFR ...

Rybrevant (amivantamab) plus chemotherapy reached a 34.3-month median survival in EGFR exon 20 insertion-positive lung cancer, Johnson & Johnson said.

Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and ...

Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment. However, evidence has recently emerged suggesting that these membranes do ...

NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible ...